WO2019177196A1 - 플라즈마를 이용한 말초신경 치료장치 - Google Patents
플라즈마를 이용한 말초신경 치료장치 Download PDFInfo
- Publication number
- WO2019177196A1 WO2019177196A1 PCT/KR2018/003883 KR2018003883W WO2019177196A1 WO 2019177196 A1 WO2019177196 A1 WO 2019177196A1 KR 2018003883 W KR2018003883 W KR 2018003883W WO 2019177196 A1 WO2019177196 A1 WO 2019177196A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasma
- peripheral neuropathy
- unit
- main body
- gas
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/44—Applying ionised fluids
- A61N1/445—Hydro-electric baths
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05H—PLASMA TECHNIQUE; PRODUCTION OF ACCELERATED ELECTRICALLY-CHARGED PARTICLES OR OF NEUTRONS; PRODUCTION OR ACCELERATION OF NEUTRAL MOLECULAR OR ATOMIC BEAMS
- H05H1/00—Generating plasma; Handling plasma
- H05H1/24—Generating plasma
- H05H1/2406—Generating plasma using dielectric barrier discharges, i.e. with a dielectric interposed between the electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/08—Arrangements or circuits for monitoring, protecting, controlling or indicating
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05H—PLASMA TECHNIQUE; PRODUCTION OF ACCELERATED ELECTRICALLY-CHARGED PARTICLES OR OF NEUTRONS; PRODUCTION OR ACCELERATION OF NEUTRAL MOLECULAR OR ATOMIC BEAMS
- H05H1/00—Generating plasma; Handling plasma
- H05H1/24—Generating plasma
- H05H1/2406—Generating plasma using dielectric barrier discharges, i.e. with a dielectric interposed between the electrodes
- H05H1/2418—Generating plasma using dielectric barrier discharges, i.e. with a dielectric interposed between the electrodes the electrodes being embedded in the dielectric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/44—Applying ionised fluids
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05H—PLASMA TECHNIQUE; PRODUCTION OF ACCELERATED ELECTRICALLY-CHARGED PARTICLES OR OF NEUTRONS; PRODUCTION OR ACCELERATION OF NEUTRAL MOLECULAR OR ATOMIC BEAMS
- H05H2245/00—Applications of plasma devices
- H05H2245/30—Medical applications
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05H—PLASMA TECHNIQUE; PRODUCTION OF ACCELERATED ELECTRICALLY-CHARGED PARTICLES OR OF NEUTRONS; PRODUCTION OR ACCELERATION OF NEUTRAL MOLECULAR OR ATOMIC BEAMS
- H05H2277/00—Applications of particle accelerators
- H05H2277/10—Medical devices
Definitions
- the present invention relates to a peripheral nerve treatment apparatus, and more particularly, to a peripheral nerve treatment apparatus using plasma that can treat peripheral neuropathy using plasma.
- Peripheral neuropathy is caused by a disease that directly damages or affects the nerve tissue, depending on the type of nerve tissue affected, sensory neuropathy, motor neuropathy. It can be distinguished by autonomic neuropathy. Sensory neuropathy causes tactile and tremors, decreased sensation to temperature changes, tingling or tingling pain, and allodynia in the skin. Motor neuropathy is accompanied by a loss of fungal sensation and muscle weakness. In autonomic neuropathy, the ability to control the bladder is weakened depending on the organs affected by the nerve, causing urinary incontinence, or causing abnormal blood pressure and heart rate (RA Hughes, 2002, BMJ, v324, pp466-469; JM Torpy et al., 2010, JAMA, v303, p1556).
- CIPN chemotherapy-induced peripheral neuropathy
- chemotherapy may require lowering the dose of chemotherapy given to the patient depending on the severity of symptoms or, in severe cases, chemotherapy itself. It has a very negative effect on the side effects. It is known that about one third of patients undergoing chemotherapy experience CIPN, and one third of patients who experience CIPN suffer permanent neurological damage (A. Bhagra RD Rao, 2007, Curr). Oncol Rep, v9, pp 290-299).
- Symptoms related to CIPN include numbness, tingling, burning, cold and pain, and loss of touch and muscle tone (T. Armstrong et al., 2005). , Oncol Nurs Forum, v32, pp305-311; C. Visovsky et al., 2008, Clin J Oncol Nurs, v12, pp243-247).
- Anticancer agents known to cause CIPN include antiplatinum, taxane, vinca alkaloids, bortezomib, or thalidomide, and the incidence of CIPN depends on the type of anticancer drug used, It is known to reach 20-75% depending on the dose and duration of administration (G. Cavaletti et al., 2011, Curr Treat Options Neurol, v13, pp180-190).
- the mechanism of neurotoxicity caused by anticancer drugs is not exactly known. However, it is assumed that the mechanisms by which anticancer drugs act on general cancer cells and the mechanisms on peripheral nervous system cells are similar to each other. It is known that anticancer agents administered to patients accumulate not only in cancer tissues but also in the peripheral nervous system, and the accumulation of such anticancer agents eventually causes neurotoxicity and cause CIPN.
- the atmospheric plasma is an ionized medium containing an active ingredient including electrons and ions, free radicals, reactive molecules and photons, and may be classified as a thermal plasma or a non-thermal plasma.
- non-thermal atmospheric pressure plasma is emerging as a new tool in biomedical applications because it can interact with the targeted biomaterial without causing thermal damage to surrounding tissues.
- the present invention has been made to solve the above problems, and an object thereof is to provide a peripheral nerve treatment apparatus using plasma that can effectively treat peripheral neuropathy using plasma.
- the device body having a body portion receiving portion formed in a shape corresponding to the body portion to treat peripheral neuropathy;
- a plasma generator for generating plasma energy to the peripheral neuropathy treatment site of the body part accommodated in the body part accommodating part;
- a gas supply unit supplying gas to the plasma generation unit;
- a gas recovery part for recovering the gas in the body part accommodating part to the outside;
- a switching control module for controlling the operation of the plasma generator, the gas supply unit, and the gas recovery unit.
- the peripheral neuropathy can be effectively treated using plasma without causing side effects or schizophrenia.
- the main body in which the body portion receiving portion is formed; And a cover body installed to be opened and closed with respect to the main body to seal the body part accommodating part.
- the body portion receiving portion is formed in the shape of a hand or foot, it is preferable to have a peripheral nerve portion receiving portion for separating the fingers or toes by the partition wall.
- the treatment effect may be enhanced by generating plasma in close proximity while the body part to treat peripheral neuropathy is located inside the treatment apparatus.
- the apparatus may further include a sealing part installed between the main body and the cover body to prevent leakage of gas and plasma from the body part accommodating part.
- the sealing unit may further include: a first sealing unit installed on surfaces of the main body and the cover body in contact with each other; And a second sealing part sealing between the body part of the patient located in the body part accommodating part and the entrance of the body part accommodating part.
- the plasma generating unit may include a low temperature atmospheric dielectric barrier (DBD) plasma installed in the main body of the apparatus to generate plasma energy around the body part accommodating part.
- DBD low temperature atmospheric dielectric barrier
- peripheral neuropathy can be effectively treated in a relatively large area.
- the switching control module may include: a module main body connected to the apparatus main body by wire or wirelessly; A switch installed in the module main body; And a switching operation unit for operating the switch.
- the switching signal of the switch may be transmitted to the device body in a wired or wireless manner to control peripheral neuropathy treatment using plasma.
- the apparatus may further include an opening and closing driver configured to automatically open and close the main body of the cover body according to the switching signal of the switching control module.
- the cover main body can be automatically opened and closed, and the patient can conveniently use it.
- the apparatus may further include an open / closed state detection unit that detects an engagement state of the cover body with respect to the main body.
- the treatment is performed only when the cover body is completely covered, thereby increasing the treatment effect and preventing leakage of the gas used for plasma generation.
- the apparatus further includes a temperature control module installed in the body to adjust the internal temperature of the body portion receiving portion.
- peripheral neuropathy can be expected to reduce the pain through the heat treatment, and also to prevent the excessive rise in temperature can be maintained to the appropriate temperature.
- the apparatus may further include a voice input unit which receives a voice input signal and transmits the voice input signal to the switching control module.
- the patient can operate the treatment device (system) through the voice command.
- peripheral nerve treatment apparatus using the plasma of the present invention it is possible to treat peripheral neuropathy using plasma, and in particular, it is possible to exclude pain-induced side effects or the occurrence of side effects in the treatment process, and thus there is an advantage in that it can be safely treated.
- peripheral neuropathy using plasma since there is no particular limitation can be easily treated, there is an advantage that can be treated regardless of time and place.
- the patient himself can operate the treatment device, it can be used conveniently.
- according to the present invention has the advantage that the structure is simple, can be manufactured to be lightweight and miniaturized to minimize the installation space, and easy movement, storage and management.
- the body portion accommodating part for accommodating peripheral nerve parts for the treatment of peripheral nerves has a curved structure of the tertiary structure in the shape of a hand and a foot, and has a closed structure, so that the body of the gentle gradient structure (the hand and the foot)
- the plasma can be irradiated in proximity to the nerves located in the core (body) can be effectively treated.
- the treatment device of the present invention is implemented as a massage chair-type treatment system, it is possible to simultaneously treat the hands and feet in a comfortable position.
- FIG. 1 is a schematic side view showing a peripheral nerve treatment apparatus using a plasma according to an embodiment of the present invention.
- FIG. 2 is a side view illustrating a state in which the cover body is covered in the state of FIG. 1.
- Figure 3 is a schematic perspective view showing a peripheral nerve treatment apparatus using a plasma according to an embodiment of the present invention.
- FIG. 4 is a schematic plan view of the main body shown in FIG. 3.
- FIG. 5 is a cross-sectional view taken along the line I-I of the main body shown in FIG.
- 6 and 7 are schematic configuration diagrams for describing the plasma generator.
- FIG. 8 is a schematic side view showing a peripheral nerve treatment apparatus using plasma according to another embodiment of the present invention.
- FIG. 9 is a view showing an experimental example and experimental results for confirming the persistence of peripheral neuropathy in a peripheral neuropathy mouse model.
- 10 is experimental data showing the change of peripheral neuropathy symptoms through behavioral experiments of peripheral neuropathy mice according to the normal temperature and atmospheric pressure plasma treatment time.
- 11 is a view showing the results of measuring the shape of axon for each nerve region by the normal temperature and pressure plasma treatment.
- FIG. 12 is a view showing the results of morphological changes of xaon and myelin through G-ratio for each nerve region after the normal-temperature atmospheric pressure plasma treatment.
- FIG. 13 is a view showing an example in which the peripheral neuropathy treatment apparatus using plasma according to an embodiment of the present invention in the form of a massage chair.
- FIG. 14 is a block diagram illustrating a peripheral neuropathy treatment apparatus using plasma according to an embodiment of the applied peripheral neuropathy of the present invention.
- a peripheral nerve treatment apparatus 100 using plasma includes a device body 110 and a treatment site accommodating part 120 provided inside the device body 110. ), A plasma generating unit 130 for intensive treatment of the peripheral nerve region accommodated in the treatment site receiving unit 120, a gas supply unit 140 for supplying gas to the plasma generating unit 130, and a plasma generating unit 130. ), A gas recovery unit 140 for recovering the remaining gas, a sealing unit 150 for sealing the inlet of the apparatus main body 110, a switching control module 160 for controlling the operation of the plasma generator 130, and It is provided with a temperature control module (210).
- the device body 110 includes a main body 111 and a cover body 113 movably coupled to the main body 111.
- the treatment part accommodating part 120 is formed to correspond to the shape of the treatment part.
- some space of the treatment site receiving portion 120 may also be formed in the cover body 113.
- the cover body 113 may be opened and closed with respect to the main body 111.
- the other end of the cover body 113 may be rotatably connected to the other end of the main body 111, and the opening and closing operation may be automatically performed by driving a separate opening and closing driving unit 170.
- the treatment site receiving unit 120 may have a hand shape to accommodate a hand of a patient to be treated. Of course, other peripheral nerve treatment sites may be formed in the shape of a foot.
- the treatment site receiving portion 120 may be formed only in the main body 111, or may be formed on the surfaces of the main body 111 and the cover body 113 in contact with each other. That is, the treatment portion receiving portion 120 is formed in a multi-dimensional and three-dimensional structure so as to correspond to the curved shape of the surface of the hand or foot.
- the finger receiving portion 121 is formed to be isolated by the partition wall so that the peripheral nerves can be accommodated in isolation from each other.
- the finger receiving portion 121 may be formed in a state where the upper portion is also covered by the cover portion 123. Therefore, the plasma energy can be treated in three dimensions with respect to the finger entered into the finger receiving portion 121 can be treated.
- the portion corresponding to the palm and the wrist of the treatment site receiving portion 120 is open to the upper surface of the main body 111 is good to allow the patient to easily insert and pull out the hand.
- the treatment portion receiving portion 120 is formed in the shape of a foot may be formed in the toe receiving portion for receiving the toes by the partition wall in place of the finger receiving portion, respectively.
- a plasma generating part may be formed in the partition to generate plasma energy to each of the finger receiving part or the toe receiving part.
- the opening and closing driver 170 is operated according to the operation control signal from the switching control module 160 to automatically open and close the cover body 113 with respect to the main body 111.
- the opening and closing drive unit 170 includes a drive motor 171 and a driven gear 175 connected to the rotation shaft of the cover body 113 so as to be connected to the drive gear 173 connected to the shaft of the drive motor 171. can do.
- the driving motor 171 may be bidirectionally driven, and the cover body 113 may be opened and closed with respect to the main body 111 by interlocking the driven gear 175 while the driving gear 173 is rotated during driving.
- the configuration of the opening and closing drive unit 170 is possible in addition to various configurations, for example, various configurations, such as an actuator, a hydraulic motor is possible. Therefore, the present invention is not limited by the specific configuration of the opening and closing drive unit 170.
- a sealing unit 150 is installed between the main body 111 and the cover body 113.
- the sealing part 150 includes a first sealing part 151 and a second sealing part 153.
- the first and second sealing parts 151 and 153 cover the main body 111 and cover the main body 111 as shown in FIG. 2, the first and second sealing parts 151 and 153 leak the gas supplied into the treatment part accommodating part 120 to the outside. It can prevent.
- the sealing unit 150 prevents leakage of the plasma generated from the treatment site receiving unit 120 to the outside.
- the first sealing part 151 is to prevent the gas and plasma from leaking through the surfaces in contact with each other in a state in which the main body 111 is covered with the cover body 113.
- the first sealing part 151 may include a sealing member installed between the main body 111 and the cover body 113.
- the sealing member may be respectively installed on the surfaces of the main body 111 and the cover body 113 in contact with each other, or may be installed to protrude only on one side thereof.
- the second sealing part 153 blocks the leakage of the gas supplied to the treatment part accommodating part 120 through a gap between the entrance of the treatment part accommodating part 120 of the apparatus main body 111 and the body of the patient. In addition, the generated plasma is blocked from leaking.
- the second sealing portion 153 is a sealing pack for supplying and recovering the sealing pack 153a installed inside the inlet of the treatment site receiving portion 120 and the compressed air for expanding and contracting the sealing pack 153a.
- the drive part 153b is provided.
- the sealing pack 153a may be installed at the inlet side of the treatment portion receiving portion 120 of the main body 11 and has a donut shape so that the sealing portion 153a may have a sufficient size to allow the treatment portion (hand) of the user to pass through. .
- the sealing pack 153a is installed so that the outside is supported by a separate protective cover (not shown), and the inside may be installed to directly contact the wrist or the arm.
- the sealing pack driving unit 153b is operated while the hand is passed through the sealing pack 153a having the above configuration, the sealing pack 153 is in close contact with the skin of the patient while being expanded, thereby accommodating the body of the patient and the treatment site receiving unit ( 120) can be sealed.
- the sealing pack driving unit 153b is at least one of an automatic compressed air supply unit for automatically supplying and recovering compressed air connected to the sealing pack 153a, or a compressed air manual supply unit for manually supplying compressed air and extracting the compressed air. It may be provided.
- the compressed air automatic supply unit may include an air pump for supplying compressed air while being driven according to an operation signal of the switch control module 160.
- the compressed air may be supplied to the sealing pack 153a to expand, or the compressed air may be taken out to shrink the sealing pack 153a.
- the compressed air manual supply unit may include a piston pump or a pumping tube connected to a hose for pumping compressed air to the sealing pack 153a and pumping the compressed air by a user's operation.
- the plasma generator 130 is installed in the apparatus main body 110 so as to radiate plasma energy to the peripheral nerve portion of the patient located in the treatment site receiving portion 120 to treat peripheral neuropathy. 2, 3 and 4, the plasma generating unit 130 is installed at a position corresponding to the peripheral nerve region of the body to be treated, thereby generating plasma energy to the position. That is, as an example, as shown in FIGS. 2 to 5, the plasma generating unit 130 is installed around the finger receiving unit 121 so that the plasma energy can be discharged to the finger surface when the portion to be treated is a hand.
- Plasma generator 130 of the above configuration preferably includes a so-called low-temperature atmospheric plasma generation module capable of large-area plasma discharge.
- Plasma generated in the low temperature atmospheric plasma generating module can prevent body damage due to high temperature, and can effectively treat CIPN without pain or side effects. The effect of treating CIPN using plasma energy will be described later in detail.
- the plasma generator 130 may be integrally formed with the apparatus main body 110 or may be manufactured separately and installed.
- An example of such a plasma generating module 130 is illustrated in FIGS. 6 and 7.
- the plasma generator 130 may have a structure of a so-called DBD (Dielectric Barrier Discharge) plasma generation method. That is, as shown in FIGS. 5 and 6, the plasma generating unit 130 is installed in the apparatus main body 110, and includes a first electrode 133 and a second electrode installed on the glass substrate 131. And a dielectric 137 disposed on the substrate 131 to insulate the 135, first and second electrodes 133 and 135. A gas supply passage for supplying gas toward the electrodes 133 and 135 may be minutely formed on the glass substrate 131.
- DBD Dielectric Barrier Discharge
- the first and second electrodes 133 and 135 formed on the substrate 131 may be stacked by a semiconductor manufacturing process and may be formed in various patterns.
- the second electrode 135 may be formed in a pattern of a mesh structure, and may be formed on the first electrode 133 between the second electrodes 135 of the mesh structure.
- the gas supply passage (gas hole) formed in the substrate 131 may also be formed through a semiconductor manufacturing process.
- the dielectric 137 is formed to cover the first and second electrodes 133 and 135, and is formed to have a predetermined thickness so as to electrically cut off the outside and effectively discharge the plasma.
- the secondary electron generation layer 138 and the hydration prevention layer 139 may be sequentially stacked on the outer side of the dielectric 137 to be further formed.
- the secondary electron generation layer 138 and the anti-hydration layer 139 may be formed by a semiconductor manufacturing process, such as the dielectric 137 and the electrodes 133 and 135.
- the secondary electron generation layer 138 may serve to regenerate more charge from the generated plasma.
- the secondary electron generation layer 138 may be selectively applied.
- the plasma generating unit 130 having such a configuration can be formed in a surface discharge structure with a desired area without being restricted by an area, and electrode formation can be made by semiconductor manufacturing technology (photolithography technology) to make a fine electrode structure. Thus, high density plasma can be generated even at low power.
- the plasma generator 130 having the above configuration supplies the gas through the gas supply path 114 of the apparatus main body 110 while applying an alternating voltage to the first and second electrodes 133 and 135. Plasma is generated between the electrodes 133 and 135.
- the interval between the first and second electrodes 133 and 135 is approximately 100 to 400 ⁇ m
- the discharge voltage is set to 1 kV or less
- the discharge current is set to have a characteristic of 10 mA or less.
- the above-described plasma generating unit 130 is only one example, it is obvious that a known DBD plasma method of various configurations can be applied. That is, various plasma methods such as low temperature atmospheric pressure plasma and room temperature atmospheric pressure plasma may be applied, and the present invention is not limited by the applied plasma method.
- the gas supply unit 140 is for supplying a gas necessary for plasma generation to the plasma generator 130, and is connected to supply a gas from the outside to the gas supply path 114 installed in the apparatus main body 110.
- the gas supply unit 140 may be operated in conjunction with an operation signal of the switching control module 160 to supply gas.
- the gas supply unit 140 may include a gas tank and a gas supply pump.
- the gas recovery unit 190 is supplied from the gas supply unit 140 and used in the plasma generating unit 130 to recover the gas inside the apparatus main body 110, that is, within the treatment site receiving unit 120.
- the gas recovery unit 190 may include a gas recovery tank (not shown), a gas recovery pump for recovering gas into the gas recovery tank, and a gas recovery path 116 installed in the apparatus main body 110.
- the switching control module 160 is for controlling the operation of the peripheral nerve treatment device 100 using the plasma of the present invention.
- the switching control module 160 may be installed in the device main body 110, but may be installed so as to be connected to a separate cable to be used at a position spaced apart from the device main body 110.
- the module main body 163 connected to the apparatus main body 110 and the cable 161, the switch 165 and the switch 165 provided in the module main body 163 are operated.
- the switching operation unit 167 may be provided.
- the switching operation unit 167 may be rotatably installed in the module main body 163, and may be rotated when the patient presses on the foot to switch the switch 165 to perform a treatment operation or to stop the operation.
- the switch may be configured as a button or touch to operate by touching to other parts of the body.
- the cable 161 may be omitted, and the wireless communication module 168 may be installed in the apparatus main body 110 to wirelessly communicate with the switch control module 160 to transmit an operation signal.
- switch control module 160 when the switch control module 160 is provided separately, when the patient treats both hands, there is an advantage of controlling the operation of the treatment apparatus using the foot, and thus it may be conveniently used.
- a separate operation unit may be provided in the apparatus main body 110 to input an operation signal using a touch pad type, or to input or set an operating condition. This may be controlled to stop the treatment operation after the operation for a predetermined time.
- the operation unit is installed on the outer surface of the cover body 113.
- a remote control module 169 may be further provided separately from the switch control module 160. That is, the remote control module 169 may be provided as a remote controller to directly control the operation of the nurse or the patient remotely.
- the operation menu of the remote control module 169 may be applied to various functions such as an on / off power control unit, a time setting unit, and a temperature setting unit.
- the opening and closing state detector 180 may be further installed between the main body 111 and the cover body 113.
- the opening / closing state detection unit 180 may include detection sensors 181 and 182 installed on at least one of the surfaces in which the main body 111 and the cover body 113 contact each other.
- the open / closed state detection unit 180 detects the open / closed state of the cover body 113, and the detected information is transmitted to the switching control module 160.
- the detection sensors 181 and 182 may include at least one selected from various types of sensors such as a contact sensor, a proximity sensor, a light emitting sensor, and a magnetic sensor.
- the open / closed state detection unit 180 may include a safety switch installed between the main body 111 and the cover body 113 to be switched according to the open / closed state of the cover body 113.
- the information detected by the open / closed state detection unit 180 having the above configuration is transmitted to the switching control module 160, and the switching control module 160 transmits the plasma generator 130 and the gas supply unit 140 according to the detected detection information. And the operation of the gas recovery unit 190. That is, the cover body 113 is completely sealed to ensure that the treatment operation using plasma is performed in a state where it is coupled to cover the main body 111, thereby completely preventing leakage of gas and ensuring safety. It can do, and increase the therapeutic effect.
- a temperature control module 210 for adjusting the temperature of the treatment site receiving portion 120 is further provided.
- the temperature control module 210 includes a heater 211 for raising the temperature inside the treatment part accommodating part 120, a temperature controller 213 and a temperature sensor 215 for controlling the driving of the heater 211. do.
- the heater 211 is installed inside the apparatus main body 100 and generates heat during driving to heat the treatment site accommodating part 120.
- the temperature controller 213 may be installed on the outside of the apparatus main body 110, and includes a setting unit (input unit) for setting a thermotherapy temperature by a user, a doctor, or a nurse. It can be controlled to be driven.
- the temperature sensor 215 measures the temperature of the treatment site accommodating part 120 and provides the temperature controller 123.
- the temperature sensor 215 may be installed at a plurality of points inside the apparatus main body 110.
- the temperature control module 210 may further include a separate cooling unit 219 for temperature control so as to prevent the temperature inside the treatment site receiving unit 120 from rising above the reference temperature.
- the cooling unit 219 may include a Peltier chip that is driven and controlled by the temperature controller 123, and the Peltier chip may be installed at a position where the heater 211 is installed and driven independently of the heater 211. have. That is, the driving of the heater 211 may be stopped, the Peltier chip may be driven, or vice versa.
- FIG 8 is a schematic side view showing a peripheral nerve treatment apparatus 100 ′ using plasma according to another embodiment of the present invention.
- the peripheral nerve treatment apparatus 100 ′ using the plasma has an apparatus body 110 having a body portion receiving portion 120 ′ corresponding to the shape of the foot to accommodate the foot. There is this.
- the apparatus main body 110 ′ includes a main main body 111 ′ and a cover main body 113 connected to the main main body 111 ′ so as to be opened and closed.
- the body part accommodating part 120 ' which can put a foot into the main body 111' is formed in a foot shape.
- the cover body 113 ' is lowered and closed while the foot is placed in the body portion receiving portion 120', and the upper portion of the main body 111 may be sealed while the cover body 113 covers the instep.
- the body portion receiving portion 120 ' is formed in the shape of a foot, can be accommodated to isolate the toes, and has a toe receiving portion that can cover up to the top.
- Plasma generator 130 ' is installed to generate plasma in a face-to-face manner near the toe receiving portion 120'.
- the sealing unit 150 as described above through the treatment apparatus 100 according to the first embodiment may be provided between the main body 111 ′ and the cover body 113 ′ to have the same function.
- the gas supply unit 140, the gas recovery unit 190, the open / close state detection unit 180, and the switching control module 160 may be understood to be similarly or similarly applied, the drawings are omitted.
- Figure 9 is shown to explain the experimental results confirming the persistence of peripheral neuropathy symptoms in the CIPN mouse model.
- mice treated with 6 and 12 minutes at room temperature and plasma at cold allodynia test felt pain compared to the control group with peripheral neuropathy.
- CIPN mice were prepared using paclitaxel, which is used as an anticancer agent, and plasma-treated effects on the symptoms of CIPN were confirmed by treating the plasma at room temperature.
- the axon of the spinal and sciatic regions was the normal group, the control group, and the plasma treated group for 6 minutes, as shown in FIG. 11.
- axon below tibial of the group treated with plasma for 6 minutes was composed of axon similar to that of the normal group, and less damaged axon.
- peripheral neuropathy As can be seen from the experimental examples above, it has been found that the therapeutic effect of peripheral neuropathy can be obtained by using plasma. It can be expected to effectively treat peripheral neuropathy in Esau. Therefore, it is possible to effectively treat while solving the problems found in conventional methods of treating peripheral neuropathy.
- peripheral neuropathy treatment apparatus (100.100 ') according to an embodiment of the present invention may be applied to the treatment system 200 in the form of a massage chair.
- the massage chair-type system body 230 is provided with a seat 231 for the patient to sit, the arm hook 233 of both sides of the seat 231 for treating the hands and arms Treatment device 100 is installed on both sides. And the lower portion of the seat 231 is provided with a treatment device (100 ') for treating peripheral neuropathy of the leg.
- the voice recognition unit 220 may be installed around the patient head holder 235 of the system main body 230.
- the voice recognition unit 220 is intended to execute an operation command by voice when the patient is difficult to operate the switching control module 160 when treating the hands and feet at the same time. Therefore, the voice recognition unit 220 receives and analyzes the voice input signal commanded by the patient by voice, and transmits the received and analyzed voice input signal to the switching control module 160. Then, the switching control module 160 may control the overall operation of the system 200 based on the signal transmitted from the voice recognition unit 220.
- the input unit 240 is an operation unit installed in the system main body 230, and is provided to set various treatment conditions (time, temperature, etc.).
- the input unit 240 may be provided in the form of a touch pad, or may include an input button and a display panel.
- the output unit 250 may include a speaker 251 installed in the system main body 230. Treatment setting information, treatment procedure information, treatment finish information, etc. set through the speaker 151 may be output as an alarm signal or a voice signal.
- the output unit 250 may include a display 253.
- the display 253 may be connected to the system main body 230 so as to correspond to the front view of the patient, or may be installed in a separate structure.
- Various treatment information, treatment procedures, and treatment termination information may also be output and transmitted through the display 253.
- a variety of information may be provided through the display 253 panel to eliminate boredom in the process of treating the patient.
- system body 230 may be provided with a massage function.
- the present invention can be used as a device for treating various types of peripheral neuropathy.
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Devices For Medical Bathing And Washing (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims (11)
- 말초신경병증을 치료할 신체부위에 대응되는 형상으로 형성된 3차원 구조의 신체부위 수용부를 가지는 장치 본체;상기 신체부위 수용부에 수용되는 신체부위의 말초신경병 치료부위로 플라즈마 에너지를 발생시키는 플라즈마 발생부;상기 플라즈마 발생부로 가스를 공급하는 가스 공급부;상기 신체부위 수용부 내의 가스를 외부로 회수하는 가스 회수부;상기 플라즈마 발생부, 상기 가스 공급부 및 상기 가스 회수부의 동작을 제어하는 스위칭 제어모듈;을 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제1항에 있어서, 상기 장치 본체는,상기 신체부위 수용부가 형성되는 메인 본체; 및상기 신체부위 수용부를 밀폐시키도록 상기 메인 본체에 대해 개폐 가능하게 설치되는 커버 본체;를 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제2항에 있어서,상기 신체부위 수용부는 손 모양 또는 발 모양으로 형성되며,손가락 또는 발가락들을 격벽에 의해 격리하여 수용하는 말초신경부 수용부를 가지는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제2항에 있어서,상기 메인 본체와 상기 커버 본체 사이에 설치되어 상기 신체부위 수용부의 가스 및 플라즈마 누수를 방지하는 실링부를 더 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제4항에 있어서, 상기 실링부는,상기 메인 본체와 상기 커버 본체의 서로 접하는 면에 설치되는 제1실링부; 및상기 신체부위 수용부에 위치하는 환자의 신체부위와 상기 신체부위 수용부의 입구 사이를 실링하는 제2실링부;를 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제1항 내지 제5항 중 어느 한 항에 있어서,상기 플라즈마 발생부는 상기 신체부위 수용부의 주변으로 플라즈마 에너지를 발생시키도록 상기 장치 본체에 설치되는 저온대기압 유전체장벽(DBD;Dielectric Barrier Discharge) 플라즈마를 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 스위칭 제어모듈은,상기 장치 본체와 유선 또는 무선으로 연결되는 모듈 본체;상기 모듈 본체에 설치되는 스위치; 및상기 스위치를 동작시키기 위한 스위칭 동작부;를 포함하여,상기 스위치의 스위칭 신호를 상기 장치 본체로 유선 또는 무선으로 전달하여 플라즈마를 이용한 말초신경병증 치료동작을 제어하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제2항 내지 제5항 중 어느 한 항에 있어서,상기 스위칭 제어모듈의 스위칭신호에 따라서 상기 커버 본체의 상기 메인 본체에 대한 개폐동작을 자동으로 동작시키는 개폐구동부를 더 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제2항 내지 제5항 어느 한 항에 있어서,상기 메인 본체에 대한 상기 커버 본체의 결합 상태를 검출하는 개폐상태 검출부를 더 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제1항 내지 제5항 중 어느 한 항에 있어서,상기 장치 본체에 설치되어 상기 신체부위 수용부의 내부온도를 조절하는 온도 조절모듈을 더 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
- 제1항 내지 제5항 중 어느 한 항에 있어서,음성입력신호를 수신하여 상기 스위칭 제어모듈로 전달하는 음성입력부를 더 포함하는 것을 특징으로 하는 플라즈마를 이용한 말초신경병증 치료장치.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0029083 | 2018-03-13 | ||
KR1020180029083A KR101978481B1 (ko) | 2018-03-13 | 2018-03-13 | 플라즈마를 이용한 말초신경 치료장치 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019177196A1 true WO2019177196A1 (ko) | 2019-09-19 |
Family
ID=66581249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/003883 WO2019177196A1 (ko) | 2018-03-13 | 2018-04-03 | 플라즈마를 이용한 말초신경 치료장치 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101978481B1 (ko) |
WO (1) | WO2019177196A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102588090B1 (ko) * | 2021-02-17 | 2023-10-13 | 강릉원주대학교산학협력단 | 플라즈마 발 치료기 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110115593A (ko) * | 2009-02-17 | 2011-10-21 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 비열성 플라즈마로 환자의 신체 일부를 치료하기 위한 치료 장치 |
KR20120136524A (ko) * | 2011-06-09 | 2012-12-20 | 전북대학교산학협력단 | 플라즈마를 이용한 생체 피부 살균장치 |
KR20170018795A (ko) * | 2015-08-10 | 2017-02-20 | 아주대학교산학협력단 | 근육 손상 치료용 질소기반 저온 대기압 플라즈마 |
US20170361078A1 (en) * | 2014-12-10 | 2017-12-21 | Devicefarm, Inc. | Onychomycosis treatment system and method |
KR20180015059A (ko) * | 2016-08-02 | 2018-02-12 | 주식회사 피글 | 플라즈마 치료 장치 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101020515B1 (ko) * | 2008-11-17 | 2011-03-09 | 최은경 | 저온 플라즈마를 이용한 의료용 멸균 및 건조 장치 |
KR101629555B1 (ko) | 2014-06-10 | 2016-06-22 | 광운대학교 산학협력단 | 플라즈마 소스를 이용한 무좀균 치료기 |
KR20160139892A (ko) | 2015-05-29 | 2016-12-07 | 주식회사 서린메디케어 | 브러시 타입 플라즈마 발생기를 이용한 두피 치료 장치 |
KR101773846B1 (ko) | 2016-05-30 | 2017-09-01 | 광운대학교 산학협력단 | 가스 공급형 비열 플라즈마 피부염 치료기 및 이의 용도 |
-
2018
- 2018-03-13 KR KR1020180029083A patent/KR101978481B1/ko active IP Right Grant
- 2018-04-03 WO PCT/KR2018/003883 patent/WO2019177196A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110115593A (ko) * | 2009-02-17 | 2011-10-21 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 비열성 플라즈마로 환자의 신체 일부를 치료하기 위한 치료 장치 |
KR20120136524A (ko) * | 2011-06-09 | 2012-12-20 | 전북대학교산학협력단 | 플라즈마를 이용한 생체 피부 살균장치 |
US20170361078A1 (en) * | 2014-12-10 | 2017-12-21 | Devicefarm, Inc. | Onychomycosis treatment system and method |
KR20170018795A (ko) * | 2015-08-10 | 2017-02-20 | 아주대학교산학협력단 | 근육 손상 치료용 질소기반 저온 대기압 플라즈마 |
KR20180015059A (ko) * | 2016-08-02 | 2018-02-12 | 주식회사 피글 | 플라즈마 치료 장치 |
Also Published As
Publication number | Publication date |
---|---|
KR101978481B1 (ko) | 2019-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mir et al. | Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes | |
US5735817A (en) | Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures | |
WO2019177196A1 (ko) | 플라즈마를 이용한 말초신경 치료장치 | |
JP4246364B2 (ja) | Aedによる治療支援の制御装置、制御支援方法、及びそれに使用されるデフィブリレータ | |
WO2017175961A1 (ko) | 손목 자극 장치 및 그의 제어 방법 | |
WO2018008801A1 (ko) | 플라즈마 및 근적외선을 이용한 피부 미용 장치 | |
CN104487132B (zh) | 用于电传送给药的电流控制 | |
WO2012138144A2 (en) | Therapeutic microrobot system for brain and spinal cord diseases | |
WO2021215552A1 (ko) | 집속 초음파 장치용 카트리지 및 이를 포함하는 집속 초음파 장치 | |
WO2009104854A2 (en) | Portable medical treatment apparatus for sebaceous glands disease using a heat source united with a light irradiation | |
WO2018184261A1 (zh) | 一种热溶祛眼袋仪 | |
WO2022220415A1 (ko) | 알에프전극의 극성 스위칭수단과 진공캡을 구비한 핸드피스 | |
WO2019203519A1 (ko) | 고주파 치료장치 | |
WO2018208063A2 (ko) | 이어 테라피 장치 | |
WO2020184880A1 (ko) | 이동형 사지 압박 순환장치 | |
CN112774016A (zh) | 一种防疫智能医护辅助设备及其辅助方法 | |
US20020078952A1 (en) | Non-invasive sinus pain relieving assembly and method | |
WO2024019202A1 (ko) | 흉부 임피던스를 이용한 심폐소생술장치 및 자동심장충격기 융합 시스템 | |
WO2022050602A1 (ko) | 터널형 자가 이동 전신 안마기 | |
WO2021221326A1 (ko) | 신체 기관에 전기 자극을 인가하는 전극선 및 이를 이용한 전극 시스템 | |
WO2020138593A1 (ko) | 약물주입장치 | |
CN1141987C (zh) | 痛经治疗装置 | |
WO2020009351A1 (ko) | 약물 주입용 팁, 핸드 피스 및 피부 처치 장치 | |
WO2015064884A1 (ko) | 자기장 프로브의 구동 궤적 및 패턴 조작이 가능한 베드형 자기장 치료 장치 | |
Edwards | Symptom relief in palliative neurological care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18909429 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18909429 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.04.2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18909429 Country of ref document: EP Kind code of ref document: A1 |